Robert G. E. Holgate
Scientific evidenceInternational Nonproprietary NameAntibodyEpitopeIn vitroImmunologyEx vivoIn silicoT cellHumanized antibodyCD52B cellIdentity (object-oriented programming)AlemtuzumabImmunogenicityScientific literatureDeimmunizationExpert groupMonoclonal antibodyDrug developmentComputational biologyMedicineBiologyImmune system
3Publications
3H-index
97Citations
Publications 3
Newest
#1Tim JonesH-Index: 8
Last. Matthew BakerH-Index: 18
view all 34 authors...
An important step in drug development is the assignment of an International Nonproprietary Name (INN) by the World Health Organization (WHO) that provides healthcare professionals with a unique and universally available designated name to identify each pharmaceutical substance. Monoclonal antibody INNs comprise a –mab suffix preceded by a substem indicating the antibody type, e.g., chimeric (-xi-), humanized (-zu-), or human (-u-). The WHO publishes INN definitions that specify how new monoclona...
43 CitationsSource
#2Richard WeldonH-Index: 5
Last. Matthew BakerH-Index: 18
view all 4 authors...
Anti-CD52 therapy has been shown to be effective in the treatment of a number of B cell malignancies, hematopoietic disorders and autoimmune diseases (including rheumatoid arthritis and multiple sclerosis); however the current standard of treatment, the humanized monoclonal antibody alemtuzumab, is associated with the development of anti-drug antibodies in a high proportion of patients. In order to address this problem, we have identified a novel murine anti-CD52 antibody which has been humanize...
24 CitationsSource
: The development of anti-therapeutic antibody immune responses can limit efficacy and reduce the safety of antibody treatments. Despite significant advances to minimize such immune responses, these responses still occur, even against fully human antibodies. Thus, the ability to assess the immunogenic potential of a therapeutic antibody can provide significant benefits during the development cycle of a therapeutic protein, and may lead to the future development of therapeutic antibodies that pos...
31 Citations
Close Researchers
Matthew Baker
H-index : 18
Babraham Institute
Tim Jones
H-index : 8
Merck & Co.
Jones Tim
Harvard University
Andreas Plückthun
H-index : 127
University of Zurich
Paul W. H. I. Parren
H-index : 95
Leiden University Medical Center
Michael R. Clark
H-index : 2
Wellington Management Company
Richard Antonius Jozef Janssen
H-index : 1
Galápagos NV
Adam Walker
H-index : 1
Andrew George Popplewell
H-index : 13
UCB
Bassil I. Dahiyat
H-index : 1
Jane A. Gross
H-index : 1
Richard Weldon
H-index : 5
Albert Einstein College of Medicine
Hendrik J. Rademaker
H-index : 2
Genmab
Martin Steegmaier
H-index : 2
Hoffmann-La Roche
Max Vásquez
H-index : 1
Alcatel-Lucent
James S. Huston
H-index : 18
Boston Biomedical Research Institute
Markus Enzelberger
H-index : 6
MorphoSys
Julian Davies
H-index : 1
John McCafferty
H-index : 21
Babraham Institute
Victoria Smith
H-index : 20
University of Ottawa
S. L. Martin
H-index : 5
The Hertz Corporation
John M. Lambert
H-index : 52
ImmunoGen, Inc.
Paul Carter
H-index : 63
University of Cambridge
Kerry A. Chester
H-index : 32
University College London
David C. Lowe
H-index : 19
AstraZeneca
Herren Wu
H-index : 38
AstraZeneca
Martin J. Glennie
H-index : 71
University of Southampton
Dennis R. Burton
H-index : 174
Massachusetts Institute of Technology
John S. Haurum
H-index : 12
Symphogen
Andrew Bradbury
H-index : 48
Los Alamos National Laboratory
Dimiter S. Dimitrov
H-index : 84
University of Pittsburgh
Thomas Schirrmann
H-index : 28
Braunschweig University of Technology
Isidro Hötzel
H-index : 19
Genentech
Stefan Dübel
H-index : 63
Braunschweig University of Technology
Mary Reilly
H-index : 2
Ashford University